The ESTEEM After Stroke program, a Phase III trial funded by the Medical Research Future Fund, is testing a community-based approach combining exercise, socialization, and cognitive activities to improve recovery and quality of life for stroke survivors. This innovative program, led by researchers from Hunter New England Local Health District, HMRI, and the University of Newcastle, aims to validate the effectiveness of environmental enrichment in stroke rehabilitation.

Error occurred while parsing the model response.

An FDA advisory panel rejected MDMA-assisted therapy for PTSD, citing concerns about trial design, abuse potential, and psychotherapy roles.

The STRIDE regimen (durvalumab plus tremelimumab) shows a significant 5-year survival benefit in patients with unresectable hepatocellular carcinoma (uHCC).

Rocket Pharmaceuticals has completed enrollment in its Phase 2 pivotal trial of RP-A501 for male patients with Danon disease.

INmune Bio's AD02 Phase 2 trial data shows a highly significant correlation (p<0.001) between EMACC and CDR-SB, a key endpoint in Alzheimer's trials.

Apnimed has completed enrollment for its Phase 3 SynAIRgy study evaluating AD109, a potential oral treatment for obstructive sleep apnea (OSA).

An independent Data and Safety Monitoring Board (DSMB) has endorsed the continuation of Cassava Sciences' Phase 3 trials for simufilam in Alzheimer's disease.

A randomized controlled trial is underway to assess the effectiveness of the Dyadic Coping Intervention of Social Participation (DCISP) for stroke survivors and their spouses.

SIFI's patent for polihexanide covers its formulation and use in treating Acanthamoeba keratitis and fungal keratitis, providing IP protection until 2040.

A randomized controlled trial demonstrated that ultrasound-guided individualized positive end-expiratory pressure (PEEP) reduces postoperative atelectasis severity in patients undergoing laparoscopic colorectal cancer resection.

Scilex Holding Company presented data on GLOPERBA® (colchicine oral solution) at the 2024 American College of Rheumatology Convergence conference.

Infigratinib, an oral FGFR3 inhibitor, significantly increased annualized height velocity in children with achondroplasia in a Phase 2 trial.

Pomerantz Law Firm is investigating Sana Biotechnology for potential securities fraud related to the suspension of its SC291 and SC379 programs.

A phase Ib/II study reveals that toripalimab combined with gemcitabine and nab-paclitaxel (GnP) demonstrates promising efficacy in patients with advanced pancreatic ductal adenocarcinoma (PDAC).

A wearable sensor measuring stride velocity (SV95C) has been validated as a primary endpoint for clinical trials in ambulatory Duchenne Muscular Dystrophy (DMD).

KP104, a dual-targeting complement inhibitor, demonstrates long-term safety and efficacy in complement inhibitor-naïve PNH patients.

A Phase III clinical trial demonstrates that a combination of amlodipine and candesartan is more effective than amlodipine alone in reducing diastolic blood pressure in hypertensive patients.

A matching-adjusted indirect comparison (MAIC) study suggests difamilast 1% cream has comparable efficacy and safety to delgocitinib in treating moderate-to-severe atopic dermatitis (AD).

A new meta-analysis explores the relationship between the subjective experiences induced by ketamine and psilocybin and their antidepressant effects.